Harbin Gloria Pharmaceuticals Co., Ltd
Shenzhen Stock ExchangeTotal Valuation
Harbin Gloria Pharmaceuticals Co., Ltd carries a market capitalization of 6.76B, placing it among publicly traded companies globally. Its enterprise value stands at 5.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.76B |
| Enterprise Value | 5.71B |
Share Statistics
Harbin Gloria Pharmaceuticals Co., Ltd currently has 2.25B shares outstanding.
| Shares Outstanding | 2.25B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Harbin Gloria Pharmaceuticals Co., Ltd trades at a trailing price-to-earnings ratio of 25.87. The price-to-sales ratio is 2.70, and the price-to-book ratio stands at 3.69.
| PE Ratio | 25.87 |
| PS Ratio | 2.70 |
| PB Ratio | 3.69 |
| P/TBV Ratio | 4.17 |
| P/FCF Ratio | 122.60 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Harbin Gloria Pharmaceuticals Co., Ltd trades at an EV/EBITDA multiple of 20.78 and an EV/FCF ratio of 100.93. The EV/Sales ratio of 2.46 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.78 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.46 |
| EV / EBITDA | 20.78 |
| EV / EBIT | 20.78 |
| EV / FCF | 100.93 |
Financial Position
Harbin Gloria Pharmaceuticals Co., Ltd maintains a current ratio of 1.23, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.52, indicating elevated leverage, while an interest coverage ratio of 62.13 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.23 |
| Quick Ratio | 0.81 |
| Debt / Equity | 3.52 |
| Debt / EBITDA | 0.27 |
| Interest Coverage | 62.13 |
Financial Efficiency
Harbin Gloria Pharmaceuticals Co., Ltd posts a return on equity of 15.23 and a return on invested capital of 11.33.
| Return on Equity (ROE) | 15.23 |
| Return on Assets (ROA) | 8.44 |
| Return on Invested Capital (ROIC) | 11.33 |
| Return on Capital Employed (ROCE) | 14.08 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 6.49 |
Taxes
Over the trailing twelve months, Harbin Gloria Pharmaceuticals Co., Ltd has paid 34.27M in income taxes, reflecting an effective tax rate of 12.12.
| Income Tax | 34.27M |
| Effective Tax Rate | 12.12 |
Stock Price Statistics
Harbin Gloria Pharmaceuticals Co., Ltd's stock has gained approximately 4.12371% over the past 52 weeks. The 50-day moving average sits at 3.03, while the 200-day moving average is 3.24.
| Beta (5Y) | N/A |
| 52-Week Price Change | 4.12371% |
| 50-Day Moving Average | 3.03 |
| 200-Day Moving Average | 3.24 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Harbin Gloria Pharmaceuticals Co., Ltd generated 2.32B in revenue and converted that into 242.21M in net income, yielding earnings per share of 0.11. EBITDA reached 274.55M, while operating income came in at 274.55M.
| Revenue | 2.32B |
| Gross Profit | 1.16B |
| Operating Income | 274.55M |
| Pretax Income | 282.71M |
| Net Income | 242.21M |
| EBITDA | 274.55M |
| EBIT | 274.55M |
| Earnings Per Share (EPS) | 0.11 |
Balance Sheet
Harbin Gloria Pharmaceuticals Co., Ltd holds 653.16M in cash and equivalents against 72.80M in total debt, resulting in a net debt position of -232.02M. Total book value stands at 1.70B, with working capital of 184.95M providing operational flexibility.
| Cash & Cash Equivalents | 653.16M |
| Total Debt | 72.80M |
| Net Debt | -232.02M |
| Equity (Book Value) | 1.70B |
| Book Value Per Share | 0.77 |
| Working Capital | 184.95M |
Cash Flow
After subtracting -52.66M in capital expenditures, free cash flow totaled -52.66M - equivalent to -0.02 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -52.66M |
| Free Cash Flow | -52.66M |
| FCF Per Share | -0.02 |
Margins
Harbin Gloria Pharmaceuticals Co., Ltd operates with a gross margin of 50.24, reflecting its pricing power and cost economics. The operating margin of 11.84 and net profit margin of 10.44 provide insight into operational efficiency.
| Gross Margin | 50.24 |
| Operating Margin | 11.84 |
| Pretax Margin | 12.19 |
| Profit Margin | 10.44 |
| EBITDA Margin | 11.84 |
Dividends & Yields
The company's payout ratio of 0.53 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | 0.53 |
| Shareholder Yield | 1.98 |
| FCF Yield | 0.82 |
Stock Splits
Harbin Gloria Pharmaceuticals Co., Ltd's most recent stock split took place on June 3, 2016 with a 1:3 split ratio.
| Last Split Date | 6/3/2016 |
| Split Ratio | 1:3 |
Scores
Harbin Gloria Pharmaceuticals Co., Ltd posts an Altman Z-Score of 5.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.67 |